Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD

OBJECTIVE: Although anti-tumour necrosis factor alpha (anti-TNFα) therapies represent a major breakthrough in IBD therapy, their cost–benefit ratio is hampered by an overall 30% non-response rate, adverse side effects and high costs. Thus, finding predictive biomarkers of non-response prior to comme...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaujoux, Renaud, Starosvetsky, Elina, Maimon, Naama, Vallania, Francesco, Bar-Yoseph, Haggai, Pressman, Sigal, Weisshof, Roni, Goren, Idan, Rabinowitz, Keren, Waterman, Matti, Yanai, Henit, Dotan, Iris, Sabo, Edmond, Chowers, Yehuda, Khatri, Purvesh, Shen-Orr, Shai S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580771/
https://www.ncbi.nlm.nih.gov/pubmed/29618496
http://dx.doi.org/10.1136/gutjnl-2017-315494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580771/
https://www.ncbi.nlm.nih.gov/pubmed/29618496
http://dx.doi.org/10.1136/gutjnl-2017-315494

Ejemplares similares